Technology Overview

Nanopharma's efforts are based on a new family of β-lactam antibiotics (N-alkylthio β-lactam) highly effective against bacterial infections caused by Staphylococcus and Bacillus microbes. Unlike traditional β-lactam antibiotics such as penicillins, which inhibit cell wall crosslinking proteins and afford a broad spectrum of bacteriocidal activity, our patented compounds are bacteriostatic in nature, highly specific and operate through a distinctly different mode of action.

We believe the inherent qualities of these new compounds are essential in order to develop better and effective alternatives to conventional antibiotics. Furthermore, contrary to most drugs which usually require demanding multi-step syntheses or semi-synthetic procedures, our beta-lactams can be prepared in a single chemical step, thus allowing us to develop new antibiotics quickly and without expensive equipment and/or elaborate techniques.

Technology Advantage

Our novel β-lactam compounds have the following advantages with respect to conventional antibiotics:

• Highly selective (narrow-spectrum)

• Unprecedented structure-activity profile for any β-lactam antibiotic.

• Bacteriostatic activity

• Distinct and unique mode of action

• Low cost and ease of production from readily available precursors